Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
暂无分享,去创建一个
H. McArthur | F. Dezem | J. Plummer | A. LeVee | F. Dadmanesh | Kellie Spector | Sujata Patil | Brigid Larkin
[1] N. Loman,et al. Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE , 2022, npj Breast Cancer.
[2] M. Küçüköner,et al. Factors influencing HER2 discordance in nonmetastatic breast cancer and the role of neoadjuvant therapy. , 2022, Future oncology.
[3] G. Curigliano,et al. Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. , 2022, Cancer discovery.
[4] Sung-Bae Kim,et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.
[5] M. Fassan,et al. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment , 2022, npj Breast Cancer.
[6] S. Gardiner,et al. Loss of HER2‐positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes , 2021, Journal of surgical oncology.
[7] S. Chandarlapaty,et al. Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer. , 2021 .
[8] I. Ellis,et al. Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer , 2021, Modern Pathology.
[9] T. Ignatov,et al. Loss of HER2 after HER2-targeted treatment , 2019, Breast cancer research and treatment.
[10] P. Fasching,et al. Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.
[11] S. André,et al. Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer. , 2019, American journal of translational research.
[12] A. Ozet,et al. Receptor discordances after neoadjuvant chemotherapy and their effects on survival. , 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[13] P. V. van Diest,et al. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.
[14] John M S Bartlett,et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.
[15] Seigo Nakamura,et al. Change in HER2 status after neoadjuvant chemotherapy and the prognostic impact in patients with primary breast cancer , 2017, Journal of surgical oncology.
[16] D. Dodwell,et al. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist. , 2016, European journal of cancer.
[17] H. Miyata,et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Z. Shao,et al. Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis , 2016, Breast Cancer Research and Treatment.
[19] A. Bilici,et al. Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer. , 2014, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[20] A. Wolff,et al. Treatment of HER2-positive breast cancer. , 2014, Breast.
[21] M. Dieci,et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Eunyoung Kang,et al. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance , 2012, Modern Pathology.
[23] Giulia Bianchi,et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[24] Peter A Fasching,et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Hortobagyi,et al. Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes , 2009, Clinical Cancer Research.
[26] D. Slamon,et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.